It's about time: Scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6957-6966

  Bevins, Robert L ^a   Zimmer, Stephen G ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; BUTYRIC ACID; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; SURVIVIN; UNCLASSIFIED DRUG; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; BUTYRATES; CAMPTOTHECIN; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN B; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 23044487814     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0836     Document Type: Article

References (55)

1. Avemann K, Knippers R, Koller T, Sogo JM. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol 1988;8:3026-34.
2. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
3. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992; 52:1823-9.
4. Palitti F. Mechanism of induction of chromosomal aberrations by inhibitors of DNA topoisomerases. Environ Mol Mutagen 1993;22:275-7.
5. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 1996;50: 1095-102.
6. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13:477-83.
7. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
8. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88.
9. Xiao H, Hasegawa T, Miyaishi O, Ohkusu K, Isobe K. Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIPI in p53-independent manner. Biochem Biophys Res Commun 1997;237:457-60.
10. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
11. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-32.
12. Greenberg VL, Williams JM, Boghaert E, Mendenhall M, Ain KB, Zimmer SG. Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid 2001;11:21-9.
13. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 2001;11:315-25.
14. Chobanian NH, Greenberg VL, Gass JM, Desimone CP, Van-Nagell JR, Zimmer SG. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res 2004;24:539-45.
15. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104:1266-9.
16. Coffey DC, Kutko MC, Click RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000;35:577-81.
17. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316-21.
18. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y. Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
19. Adachi M, Zhang Y, Zhao X et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 2004;10:3853-62.
20. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61:1327-33.
21. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
22. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987;23:1283-7.
23. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
24. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102:2615-22.
25. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003-7.
26. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580-4.
27. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000;97:13103-7.
28. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54.
29. Pennati M, Binda M, De-Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004;25:1129-36.
30. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63: 3637-45.
31. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003;66:1537-45.
32. Guo F, Sigua C, Tao J. et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9.
33. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2004; 64:6626-34.
34. Sato N, Ohta T, Kitagawa H, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 2004;24: 679-85.
35. Nair AR, Boersma LJ, Schiltz L, Chaudhry MA, Muschel RJ, Chaudry A. Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyl-transferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett 2001;166:55-64.
36. Bom D, Curran DP, Kruszewski S, et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 2000;43:3970-80.
37. Bom D, Curran DP, Zhang J, et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 2001;74:325-33.
38. Bom D, Curran DP, Chavan AJ, et al. Novel A,B,E,ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 1999;42:3018-22.
39. Wood DE, Newcomb EW. Caspase-dependent activation of calpain during drug-induced apoptosis. J Biol Chem 1999;274:8309-15.
40. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 2000;64:821-46.
41. 2 arrest following DNA damage. Oncogene 1996;13:1647-57.
42. 34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-5.
43. Fournel M, Trachy-Bourget MC, Yan PT, et al. Sulfonamide anilides. a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 2002;62:4325-30.
44. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 2002;132:1012-7.
45. Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 2001;276:4539-42.
46. Adachi N, Nomoto M, Kohno K, Koyama H. Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene 2000;245: 49-57.
47. Kurz EU Wilson SE, Leader KB, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II α expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001;1:121-31.
48. Tsai SC, Valkov N, Yang VVM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26: 349-53.
49. Chen X, Lowe M, Herliczek T, et al. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(I) arrest. J Natl Cancer Inst 2000;92:1999-2008.
50. Chatterjee D, Wyche JH, Pantazis P. Up-regulation of cyclin BI and cdc2 expression during9-nitrocamptothecin-induced regression of DU145 prostate tumor. Anticancer Res 2000;20:4477-82.
51. Maity A, McKenna WG, Muschel RJ. Evidence for post-transcriptional regulation of cyclin B1 mBRA in the cell cycle and following irradiation in HeLa cells. EMBO J 1995;14:603-9.
52. Holloway SL, Glotzer M, King RW, Murray AW. Anaphase is initiated by proteolysis rather than by the inactivation of maturation-promoting factor. Cell 1993; 73:1393-402.
53. Seufert W, Futcher B, Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 1995;373:78-81.
54. 2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. Acta Biochim Pol 2002; 49:109-19.
55. Griffith TS, Kemp TJ. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 2003;52:175-84.